Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcitonin and postmenopausal bone loss.

J Y Reginster1, R Deroisy, M P Lecart

  • 1Rheumatology and Physical Medicine Department, University of Liège, Belgium.

Experimental Gerontology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2003
Same author

Structure of bacteriocin AS-48: from soluble state to membrane bound state.

Journal of molecular biology·2003
Same author

Crural artery bypass with the autogenous greater saphenous vein.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2003
Same author

[Predictive value of prenatal MRI in the diagnosis of thoracic congenital malformations].

Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica·2003
Same author

Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.

Neoplasma·2003
Same author

Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control.

Diabetic medicine : a journal of the British Diabetic Association·2003

Calcitonin (CT) levels are lower in postmenopausal women and osteoporotic patients. Intranasal salmon calcitonin (SCT) effectively treats Paget

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Postmenopausal bone loss is a significant health concern.
  • The role of calcitonin (CT) in bone metabolism requires further elucidation.
  • Reduced CT levels are observed in postmenopausal women and osteoporotic individuals.

Purpose of the Study:

  • To investigate the role of calcitonin (CT) in postmenopausal bone loss.
  • To assess the efficacy of salmon calcitonin (SCT) nasal spray in treating Paget's disease and preventing postmenopausal osteoporosis.

Main Methods:

  • Studied CT metabolism in pre- and postmenopausal women.
  • Investigated CT-antibody interactions in rabbits.
  • Conducted clinical trials using intranasal SCT in patients with Paget's disease and healthy postmenopausal women.

Related Experiment Videos

Main Results:

  • Postmenopausal women exhibited significantly lower basal CT levels.
  • CT production rates were lower in osteoporotic patients compared to healthy controls.
  • Intranasal SCT improved clinical and biochemical markers in Paget's disease and counteracted bone loss in early postmenopausal women.

Conclusions:

  • Calcitonin plays a role in bone metabolism, with reduced levels associated with postmenopausal bone loss and osteoporosis.
  • Intranasal salmon calcitonin is effective in treating Paget's disease.
  • Intranasal CT shows promise for preventing postmenopausal osteoporosis.